Martin Luck
Overview
Explore the profile of Martin Luck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luck M, Klinken-Uth S, Kleinebudde P
Int J Pharm X
. 2024 Dec;
8:100303.
PMID: 39635294
Elastic recovery ( ) has been investigated and discussed extensively in the field of tableting. However, until now only limited data is available regarding in roll compaction. Therefore, a previously...
2.
Herrera F, Torres D, Laborde A, Jordan R, Berruezo L, Roccia Rossi I, et al.
Pathogens
. 2024 Nov;
13(11).
PMID: 39599486
The epidemiology of bacteremia and the antibiotic resistance profile (ARP) of Gram-negative bacilli (GNB) in hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT) patients may differ according to geographic...
3.
Herrera F, Torres D, Laborde A, Jordan R, Manez N, Berruezo L, et al.
Microorganisms
. 2024 Jan;
12(1).
PMID: 38258022
Few studies have evaluated the efficacy of ceftazidime-avibactam (CA) for carbapenemase-producing Enterobacterales bacteremia (KPC-PEB) in high-risk neutropenic patients. This is a prospective multicenter observational study in high-risk neutropenic patients with...
4.
Luck M, Klinken S, Kleinebudde P
J Pharm Sci
. 2023 Oct;
113(4):1020-1028.
PMID: 37839611
Process Analytical Technology (PAT) plays a crucial role in the design of today's manufacturing lines as continuous manufacturing becomes more important. Until now PAT tools to measure the ribbon solid...
5.
Herrera F, Torres D, Laborde A, Berruezo L, Jordan R, Roccia Rossi I, et al.
Antibiotics (Basel)
. 2023 Feb;
12(2).
PMID: 36830136
Identifying the risk factors for carbapenem-resistant Enterobacterales (CRE) bacteremia in cancer and hematopoietic stem cell transplantation (HSCT) patients would allow earlier initiation of an appropriate empirical antibiotic treatment. This is...
6.
Luck M, De Saeger M, Kleinebudde P
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36365219
Influence of the roll speed () during roll compaction on ribbon, granule, tablet properties and its effect on the prediction of the ribbon solid fraction at-gap is often neglected or...
7.
Schwach G, Oudry N, Giliberto J, Broqua P, Luck M, Lindner H, et al.
Eur J Pharm Biopharm
. 2004 Apr;
57(3):441-6.
PMID: 15093591
Poly (DL-lactide-co-glycolide) microparticles (MP) containing a highly potent peptidic gonadotropin releasing hormone antagonist (degarelix) of interest in the prostate cancer indication were screened for biological performance. Efficacy was tested in...
8.
Schwach G, Oudry N, Delhomme S, Luck M, Lindner H, Gurny R
Eur J Pharm Biopharm
. 2003 Nov;
56(3):327-36.
PMID: 14602174
The formulation of a new GnRH antagonist (degarelix) in biodegradable poly(DL-lactide-co-glycolide) (PLGA) microparticles was investigated for the development of a 3-month sustained release formulation to treat prostate cancer. The aim...